Alberto Olaya-Vargas

Alberto Olaya-Vargas

Auto-generated profile, based on publicly available information

Alberto Olaya-Vargas

Instituto Nacional de Pediatría

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2017 in Blood
Verified
Journal Article
Closed access
PDF file
CMCharline Miot
Charline Miot
KIKohsuke Imai
Kohsuke Imai
CIChihaya Imai
Chihaya Imai
AMAnthony J. Mancini
Anthony J. Mancini
ZKZeynep Yesim Kucuk
Zeynep Yesim Kucuk
CPCapucine Picard
Capucine Picard
X-linked recessive ectodermal dysplasia with immunodeficiency is a rare primary immunodeficiency caused by hypomorphic mutations of the IKBKG gene encoding the nuclear factor κB essential modulator (NEMO) protein. This condition displays enormous allelic, immunological, and clinical heterogeneity, and therapeutic decisions are difficult because NEMO operates in both hematopoietic and nonhematopoietic cells. Hematopoietic stem cell transplantation (HSCT) is potentially life-saving, but the small number of case reports available suggests it has been reserved for only the most severe cases. Here, we report the health status before HSCT, transplantation outcome, and clinical follow-up for a series of 29 patients from unrelated kindreds from 11 countries. Between them, these patients carry 23 different hypomorphic IKBKG mutations. HSCT was performed from HLA-identical related donors (n = 7), HLA-matched unrelated donors (n = 12), HLA-mismatched unrelated donors (n = 8), and HLA-haploidentical related donors (n = 2). Engraftment was documented in 24 patients, and graft-versus-host disease in 13 patients. Up to 7 patients died 0.2 to 12 months after HSCT. The global survival rate after HSCT among NEMO-deficient children was 74% at a median follow-up after HSCT of 57 months (range, 4-108 months). Preexisting mycobacterial infection and colitis were associated with poor HSCT outcome. The underlying mutation does not appear to have any influence, as patients with the same mutation had different outcomes. Transplantation did not appear to cure colitis, possibly as a result of cell-intrinsic disorders of the epithelial barrier. Overall, HSCT can cure most clinical features of patients with a variety of IKBKG mutations. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Global survival rate was 74% at a median follow-up after HSCT of 57 months. Preexisting mycobacterial infection and colitis were associated with poor HSCT outcome.

13 August 2012 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
RRRoberto Rivera‐Luna
Roberto Rivera‐Luna
CCCecilia Correa‐González
Cecilia Correa‐González
EAEduardo Altamirano‐Alvarez
Eduardo Altamirano‐Alvarez
FSFernando Sánchez‐Zubieta
Fernando Sánchez‐Zubieta
RCRocio Cárdenas‐Cardós
Rocio Cárdenas‐Cardós
MAManuel Aguilar‐Romo
Manuel Aguilar‐Romo

1 December 2016 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RRRoberto Rivera-Luna
Roberto Rivera-Luna
MZMarta Zapata-Tarres
Marta Zapata-Tarres
JSJaime Shalkow
Jaime Shalkow
LVLiliana Velasco-Hidalgo
Liliana Velasco-Hidalgo
AOAlberto Olaya-Vargas
Alberto Olaya-Vargas
MAMarco R Aguilar-Ortiz
Marco R Aguilar-Ortiz

29 October 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RRRoberto Rivera-Luna
Roberto Rivera-Luna
JSJaime Shalkow
Jaime Shalkow
LVLiliana Velasco-Hidalgo
Liliana Velasco-Hidalgo
RCRocio Cárdenas-Cardós
Rocio Cárdenas-Cardós
MZMarta Zapata-Tarrés
Marta Zapata-Tarrés
FPFrancisco Pantoja-Guillen
Francisco Pantoja-Guillen
All the children registered at the National Council for the Prevention and Treatment of Childhood Cancer were analyzed. The rationale for this Federal Government Council is to financially support the treatment of all children registered into this system. All patients are within a network of 55 public certified hospitals nationwide. In the current study, data from 2007 to 2012 are presented for all patients (0–18 years) with a pathological diagnosis of leukemia, lymphoma and solid tumors. The parameters analyzed were prevalence, incidence, mortality, and abandonment rate. A diagnosis of cancer was documented in 14,178 children. The incidence was of 156.9/million/year (2012). The median age was 4.9. The most common childhood cancer is leukemia, which occurs in 49.8% of patients (2007–2012); and has an incidence rate of 78.1/million/year (2012). The national mortality rate was 5.3/100,000 in 2012, however in the group between 15 to 18 years it reaches a level of 8.6. The study demonstrates that there is a high incidence of childhood cancer in Mexico. In particular, the results reveal an elevated incidence and prevalence of leukemia especially from 0 to 4 years. Only 4.7% of these patients abandoned treatment. The clinical outcome for all of the children studied improved since the establishment of this national program.

1 October 2017 in Toxicology in Vitro
Verified
Journal Article
Closed access
MNM.P. Navarrete-Meneses
M.P. Navarrete-Meneses
CSConsuelo Salas
Consuelo Salas
MSM. Sanabrais-Jiménez
M. Sanabrais-Jiménez
JSJ. Santana-Hernández
J. Santana-Hernández
ASA. Serrano-Cuevas
A. Serrano-Cuevas
PPPatricia Pérez-Vera
Patricia Pérez-Vera

24 January 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AHAlejandrina Hernández-López
Alejandrina Hernández-López
AOAlberto Olaya-Vargas
Alberto Olaya-Vargas
JBJuan Carlos Bustamante-Ogando
Juan Carlos Bustamante-Ogando
Angélica Meneses AcostaAngélica Meneses Acosta
Angélica Meneses Acosta
CAR-T cell therapy has shown promising results in treating malignant hematologic diseases. The principle of this therapy is based on the use of genetically modified T lymphocytes to express a Chimeric Antigen Receptor (CAR) on their membrane that specifically recognizes an antigen predominantly expressed on target cells. The molecular design of the CAR, along with advancements in molecular techniques and the development of “omics”, has opened the possibility of discovering new therapeutic targets and thereby expanding the range of diseases treated with CAR-T cells beyond the use of anti-CD19 and anti-BCMA for hematologic cancer. This review summarizes the novel therapeutic targets that are currently used in clinical trials with CAR-T cell therapy on autoimmune diseases and other challenging conditions, such as cardiac fibrosis, and different infections. Additionally, challenges and novel opportunities are discussed for expanding clinical access to this innovative therapy.